These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 21492400

  • 1. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men.
    Kaufman JM, Miller MG, Garwin JL, Fitzpatrick S, McWhirter C, Brennan JJ.
    J Sex Med; 2011 Jul; 8(7):2079-89. PubMed ID: 21492400
    [Abstract] [Full Text] [Related]

  • 2. One-year efficacy and safety study of a 1.62% testosterone gel in hypogonadal men: results of a 182-day open-label extension of a 6-month double-blind study.
    Kaufman JM, Miller MG, Fitzpatrick S, McWhirter C, Brennan JJ.
    J Sex Med; 2012 Apr; 9(4):1149-61. PubMed ID: 22321357
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
    Grober ED, Khera M, Soni SD, Espinoza MG, Lipshultz LI.
    Int J Impot Res; 2008 Apr; 20(2):213-7. PubMed ID: 17898800
    [Abstract] [Full Text] [Related]

  • 4. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men.
    Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N, Testosterone Gel Study Group.
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2839-53. PubMed ID: 10946892
    [Abstract] [Full Text] [Related]

  • 5. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
    Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Longstreth J, Berman N.
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4500-10. PubMed ID: 11134099
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Absorption of testosterone gel 1% (Testim) from three different application sites.
    Guay AT, Smith TM, Offutt LA.
    J Sex Med; 2009 Sep; 6(9):2601-10. PubMed ID: 19549089
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Serum testosterone levels in non-dosed females after secondary exposure to 1.62% testosterone gel: effects of clothing barrier on testosterone absorption.
    Stahlman J, Britto M, Fitzpatrick S, McWhirter C, Testino SA, Brennan JJ, Zumbrunnen TL.
    Curr Med Res Opin; 2012 Feb; 28(2):291-301. PubMed ID: 22188558
    [Abstract] [Full Text] [Related]

  • 13. A novel testosterone 2% gel for the treatment of hypogonadal males.
    Dobs AS, McGettigan J, Norwood P, Howell J, Waldie E, Chen Y.
    J Androl; 2012 Feb; 33(4):601-7. PubMed ID: 21979302
    [Abstract] [Full Text] [Related]

  • 14. Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months.
    Morgentaler A, Benesh JA, Denes BS, Kan-Dobrosky N, Harb D, Miller MG.
    J Sex Med; 2014 Nov; 11(11):2818-25. PubMed ID: 25131184
    [Abstract] [Full Text] [Related]

  • 15. The Effect of Testosterone Topical Solution in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel.
    Burns PR, Kim ED, Ruff DD, Seftel AD.
    Am J Mens Health; 2018 May; 12(3):524-530. PubMed ID: 26438471
    [Abstract] [Full Text] [Related]

  • 16. Effect of application site, clothing barrier, and application site washing on testosterone transfer with a 1.62% testosterone gel.
    Stahlman J, Britto M, Fitzpatrick S, McWhirter C, Testino SA, Brennan JJ, Zumbrunnen TL.
    Curr Med Res Opin; 2012 Feb; 28(2):281-90. PubMed ID: 22188557
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men.
    Mazer N, Bell D, Wu J, Fischer J, Cosgrove M, Eilers B, BS, RN,.
    J Sex Med; 2005 Mar; 2(2):213-26. PubMed ID: 16422889
    [Abstract] [Full Text] [Related]

  • 18. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone.
    Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H.
    J Urol; 2004 Aug; 172(2):658-63. PubMed ID: 15247755
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men.
    Wang C, Ilani N, Arver S, McLachlan RI, Soulis T, Watkinson A.
    Clin Endocrinol (Oxf); 2011 Dec; 75(6):836-43. PubMed ID: 21689131
    [Abstract] [Full Text] [Related]

  • 20. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study).
    Buvat J, Montorsi F, Maggi M, Porst H, Kaipia A, Colson MH, Cuzin B, Moncada I, Martin-Morales A, Yassin A, Meuleman E, Eardley I, Dean JD, Shabsigh R.
    J Sex Med; 2011 Jan; 8(1):284-93. PubMed ID: 20704642
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.